Diagnostics Rapidly Evolving, Ideal Companions in Drug R&D

Winter, Peter
May 2013
BioWorld Insight;5/13/2013, Vol. 21 Issue 20, p2
The article discusses how research and development of drugs can be assisted by the rapidly evolving companion diagnostics. It informs that companion diagnostics co-developed with potential therapeutics can help drug companies in getting the required approvals for the drugs. It also talks about pharmaceutical company Pfizer Inc's targeted therapy Xalkori and Roche AG's Zelboraf (vermurafenib) using companion diagnostics to get approval from the U.S. Food and Drug Administration (FDA).


Related Articles

  • Pharmaceutical Company Round-up.  // PharmaWatch: Monthly Review;Jun2009, Vol. 8 Issue 6, p3 

    The article offers updates related to the pharmaceutical industry in the U.S. It notes that the federal government is investing $1 billion for the development of a vaccine. GlaxoSmithKline (GSK) and Pfizer Inc. announce their partnership on HIV businesses. A drug called Avistin from Genentech...

  • Pharma sector's war versus counterfeit drugs intensifies. Dickson, Virgil // PRWeek (U.S. Edition);Jun2012, Vol. 15 Issue 6, p16 

    The article focuses on counterfeiting of medicines in the U.S. It states that the U.S. Food & Drug Administration (FDA) found that cancer drug Avastin from F. Hoffmann-La Roche Ltd. did not have the active ingredient. It mentions that counterfeit versions of at least 60 products of Pfizer Inc....

  • Targeted Cancer Drugs Market Analysed by Espicom in New Topical Report Now Available at MarketPublishers.com.  // Biomedical Market Newsletter;2/28/2012, Vol. 21, p1 

    The article reports on the approval of two new molecularly-targeted cancer drugs by the U.S. Food and Drug Administration (FDA) which includes the Xalkori (crizotinib) from Pfizer Inc. and Zelboraf (vemurafenib) from F. Hoffmann-La Roche Ltd. It discusses the increasing market opportunities for...

  • Actemra poised to launch IL-6 inhibitors. Melton, Lisa; Coombs, Amy // Nature Biotechnology;Sep2008, Vol. 26 Issue 9, p957 

    The article discusses the U.S. Food and Drug Administration's decision to support the Swiss pharmaceutical company Roche in using the humanized monoclonal antibody (mAb) Acterma to treat rheumatoid arthritis. This would be a major shift in how biologics have traditionally been used to treat...

  • Biotech Saved My Life. Baugus, Kimberly // Equities;Nov2007, Vol. 55 Issue 5, p52 

    The article focuses on biotechnology companies Genentech, Roche, and Pfizer, which have had significant impact on cancer treatment through ongoing research and development of new, innovative cancer drugs and therapies. It states that the battle against cancer can be won only with continued...

  • FDA ROUNDUP.  // MondayMorning;7/9/2012, Vol. 20 Issue 27, p1 

    The article offers news briefs related to the U.S. Food & Drug Administration (FDA) in 2012. The agency approved a generic version of Pfizer's Lyrica nerve pain drug from Mumbai, India-based Lupin Ltd. Roche Holding AG obtained clearance for its DNA test to monitor the development of a treatment...

  • Larger companies dominate cancer companion diagnostic approvals. Schmidt, Charles // Nature Biotechnology;Nov2011, Vol. 29 Issue 11, p955 

    The article reports on biopharmaceutical companies producing cancer medicines with companion diagnostics. Companies like Roche, Genentech and Pfizer have produced drugs and diagnostics approved by the U.S. Food and Drug Administration (FDA). The firms assert that it speeds up clinical trials and...

  • REPORTER'S NOTEBOOK.  // Drug Store News;1/16/2006, Vol. 28 Issue 1, p27 

    The article reports on several developments related to pharmaceutical industries in the U.S. The judge of the Federal District Court of Delaware, Joseph Farnan, has ruled in favor of Pfizer Inc. the validity of the patents protecting atorvastatin, the active ingredient of Lipitor. Orenica,...

  • What T-DM1 Means for Roche And Biotechs on the AA Path. Morrison, Trista // BioWorld Insight;9/27/2010, Vol. 18 Issue 39, p1 

    The article reports on the issue regarding the ruling of the U.S. Food and Drug Administration (FDA). It states that Roche's AG's bevacizumab and ImmunoGen Inc.'s breast cancer drug trastuzumab-DMI did not qualify for review under the accelerated approval pathway. It notes that FDA rejected the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics